CEACAM5 and neoplasm: While 37% of mGITRL-FP alone and 68% of CEA.Tg mice treated with vaccine were cured (Figure 1) of MC32A tumors, it was of interest to determine the relative protective strength against subsequent challenge with MC32A tumor cells.